Tennessee House Bill HB2897

Tennessee 2023-2024 Regular Session

• Introduced: 1/31/24
• Refer: 2/13/24
• Refer: 3/12/24
• Refer: 3/20/24
• Chaptered: 5/13/24
• Passed: 5/13/24

Caption

AN ACT to amend Tennessee Code Annotated, Title 47, Chapter 18; Title 56; Title 63 and Title 71, relative to prescription drugs.

Impact

If enacted, HB 2897 would significantly influence how pharmacies operate, mandating a new level of disclosure that could lead to cost savings for consumers. By compelling pharmacies to reach out to patients about pricing, the legislation aims to foster a more informed patient base, which may alter buying behaviors and improve affordability of medications. Moreover, the bill's introduction of legal immunity for pharmacies that comply with these requirements may encourage broader adoption of such practices across the state, impacting existing pharmacy policies and procedures regarding medication dispensation.

Summary

House Bill 2897 aims to amend several sections of the Tennessee Code Annotated concerning prescription drugs. The general thrust of the bill is to require pharmacies to make efforts to inform patients about the lowest available costs for prescription medications, including generic alternatives. This is intended to empower consumers to make more informed decisions when filling or renewing prescriptions, enhancing their choice and potentially reducing out-of-pocket expenses. The bill encourages pharmacies to engage in transparent communication with patients about pricing options and discount programs available to them.

Sentiment

The sentiment surrounding HB 2897 appears to be predominantly positive, especially among advocates for consumer rights and healthcare transparency. Proponents view the bill as a crucial step toward reducing the financial burden associated with prescription medications by promoting cost-awareness among patients. However, there may also be concerns or opposition from entities worried about the operational implications for pharmacies and how such requirements could complicate existing workflows or affect profit margins.

Contention

Notably, some points of contention include the balance of transparency with pharmacy operational efficiency and the potential for increased patient inquiries. While the intent is to benefit consumers, the extra responsibilities placed on pharmacies could lead to debates regarding the practicality of implementation and compliance. Additionally, the immunity provided to pharmacies may raise questions among critics about accountability in cases where patients are misinformed or compromised by the actions taken under this new regulation.